Evaluation of early-phase [18F]-florbetaben PET acquisition in clinical routine cases
In recent years several [18F]-labelled amyloid PET tracers have been developed and have obtained clinical approval. There is accumulating evidence that early (post injection) acquisitions with these tracers are equally informative as conventional blood flow and metabolism studies for diagnosis of Al...
Saved in:
| Published in | NeuroImage clinical Vol. 14; no. C; pp. 77 - 86 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier Inc
01.01.2017
Elsevier |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | In recent years several [18F]-labelled amyloid PET tracers have been developed and have obtained clinical approval. There is accumulating evidence that early (post injection) acquisitions with these tracers are equally informative as conventional blood flow and metabolism studies for diagnosis of Alzheimer's disease, but there have been few side-by-side studies. Therefore, we investigated the performance of early acquisitions of [18F]-florbetaben (FBB) PET compared to [18F]-fluorodeoxyglucose (FDG) PET in a clinical setting.
All subjects were recruited with clinical suspicion of dementia due to neurodegenerative disease. FDG PET was undertaken by conventional methods, and amyloid PET was performed with FBB, with early recordings for the initial 10min (early-phase FBB), and late recordings at 90–110min p.i. (late-phase FBB). Regional SUVR with cerebellar and global mean normalization were calculated for early-phase FBB and FDG PET. Pearson correlation coefficients between FDG and early-phase FBB were calculated for predefined cortical brain regions. Furthermore, a visual interpretation of disease pattern using 3-dimensional stereotactic surface projections (3D-SSP) was performed, with assessment of intra-reader agreement.
Among a total of 33 patients (mean age 67.5±11.0years) included in the study, 18 were visually rated amyloid-positive, and 15 amyloid-negative based on late-phase FBB scans. Correlation coefficients for early-phase FBB vs. FDG scans displayed excellent agreement in all target brain regions for global mean normalization. Cerebellar normalization gave strong, but significantly lower correlations. 3D representations of early-phase FBB visually resembled the corresponding FDG PET images, irrespective of the amyloid-status of the late FBB scans.
Early-phase FBB acquisitions correlate on a relative quantitative and visual level with FDG PET scans, irrespective of the amyloid plaque density assessed in late FBB imaging. Thus, early-phase FBB uptake depicts a metabolism-like image, suggesting it as a valid surrogate marker for synaptic dysfunction, which could ultimately circumvent the need for additional FDG PET investigation in diagnosis of dementia.
•Early-phase [18F]-florbetaben uptake depicts a metabolism-like image•Strong relative quantitative and visual correlations of early-phase [18F]-florbetaben uptake with FDG images•A two-phase [18F]-florbetaben protocol might give combined neurodegeneration and amyloid pathology biomarker information•Early-phase [18F]-florbetaben PET could ultimately circumvent the need for an additional FDG-PET in the dementia work-up. |
|---|---|
| AbstractList | In recent years several [18F]-labelled amyloid PET tracers have been developed and have obtained clinical approval. There is accumulating evidence that early (post injection) acquisitions with these tracers are equally informative as conventional blood flow and metabolism studies for diagnosis of Alzheimer's disease, but there have been few side-by-side studies. Therefore, we investigated the performance of early acquisitions of [18F]-florbetaben (FBB) PET compared to [18F]-fluorodeoxyglucose (FDG) PET in a clinical setting.All subjects were recruited with clinical suspicion of dementia due to neurodegenerative disease. FDG PET was undertaken by conventional methods, and amyloid PET was performed with FBB, with early recordings for the initial 10min (early-phase FBB), and late recordings at 90-110min p.i. (late-phase FBB). Regional SUVR with cerebellar and global mean normalization were calculated for early-phase FBB and FDG PET. Pearson correlation coefficients between FDG and early-phase FBB were calculated for predefined cortical brain regions. Furthermore, a visual interpretation of disease pattern using 3-dimensional stereotactic surface projections (3D-SSP) was performed, with assessment of intra-reader agreement.Among a total of 33 patients (mean age 67.5±11.0years) included in the study, 18 were visually rated amyloid-positive, and 15 amyloid-negative based on late-phase FBB scans. Correlation coefficients for early-phase FBB vs. FDG scans displayed excellent agreement in all target brain regions for global mean normalization. Cerebellar normalization gave strong, but significantly lower correlations. 3D representations of early-phase FBB visually resembled the corresponding FDG PET images, irrespective of the amyloid-status of the late FBB scans.Early-phase FBB acquisitions correlate on a relative quantitative and visual level with FDG PET scans, irrespective of the amyloid plaque density assessed in late FBB imaging. Thus, early-phase FBB uptake depicts a metabolism-like image, suggesting it as a valid surrogate marker for synaptic dysfunction, which could ultimately circumvent the need for additional FDG PET investigation in diagnosis of dementia. Objectives: In recent years several [18F]-labelled amyloid PET tracers have been developed and have obtained clinical approval. There is accumulating evidence that early (post injection) acquisitions with these tracers are equally informative as conventional blood flow and metabolism studies for diagnosis of Alzheimer's disease, but there have been few side-by-side studies. Therefore, we investigated the performance of early acquisitions of [18F]-florbetaben (FBB) PET compared to [18F]-fluorodeoxyglucose (FDG) PET in a clinical setting. Methods: All subjects were recruited with clinical suspicion of dementia due to neurodegenerative disease. FDG PET was undertaken by conventional methods, and amyloid PET was performed with FBB, with early recordings for the initial 10 min (early-phase FBB), and late recordings at 90–110 min p.i. (late-phase FBB). Regional SUVR with cerebellar and global mean normalization were calculated for early-phase FBB and FDG PET. Pearson correlation coefficients between FDG and early-phase FBB were calculated for predefined cortical brain regions. Furthermore, a visual interpretation of disease pattern using 3-dimensional stereotactic surface projections (3D-SSP) was performed, with assessment of intra-reader agreement. Results: Among a total of 33 patients (mean age 67.5 ± 11.0 years) included in the study, 18 were visually rated amyloid-positive, and 15 amyloid-negative based on late-phase FBB scans. Correlation coefficients for early-phase FBB vs. FDG scans displayed excellent agreement in all target brain regions for global mean normalization. Cerebellar normalization gave strong, but significantly lower correlations. 3D representations of early-phase FBB visually resembled the corresponding FDG PET images, irrespective of the amyloid-status of the late FBB scans. Conclusions: Early-phase FBB acquisitions correlate on a relative quantitative and visual level with FDG PET scans, irrespective of the amyloid plaque density assessed in late FBB imaging. Thus, early-phase FBB uptake depicts a metabolism-like image, suggesting it as a valid surrogate marker for synaptic dysfunction, which could ultimately circumvent the need for additional FDG PET investigation in diagnosis of dementia. OBJECTIVESIn recent years several [18F]-labelled amyloid PET tracers have been developed and have obtained clinical approval. There is accumulating evidence that early (post injection) acquisitions with these tracers are equally informative as conventional blood flow and metabolism studies for diagnosis of Alzheimer's disease, but there have been few side-by-side studies. Therefore, we investigated the performance of early acquisitions of [18F]-florbetaben (FBB) PET compared to [18F]-fluorodeoxyglucose (FDG) PET in a clinical setting.METHODSAll subjects were recruited with clinical suspicion of dementia due to neurodegenerative disease. FDG PET was undertaken by conventional methods, and amyloid PET was performed with FBB, with early recordings for the initial 10 min (early-phase FBB), and late recordings at 90-110 min p.i. (late-phase FBB). Regional SUVR with cerebellar and global mean normalization were calculated for early-phase FBB and FDG PET. Pearson correlation coefficients between FDG and early-phase FBB were calculated for predefined cortical brain regions. Furthermore, a visual interpretation of disease pattern using 3-dimensional stereotactic surface projections (3D-SSP) was performed, with assessment of intra-reader agreement.RESULTSAmong a total of 33 patients (mean age 67.5 ± 11.0 years) included in the study, 18 were visually rated amyloid-positive, and 15 amyloid-negative based on late-phase FBB scans. Correlation coefficients for early-phase FBB vs. FDG scans displayed excellent agreement in all target brain regions for global mean normalization. Cerebellar normalization gave strong, but significantly lower correlations. 3D representations of early-phase FBB visually resembled the corresponding FDG PET images, irrespective of the amyloid-status of the late FBB scans.CONCLUSIONSEarly-phase FBB acquisitions correlate on a relative quantitative and visual level with FDG PET scans, irrespective of the amyloid plaque density assessed in late FBB imaging. Thus, early-phase FBB uptake depicts a metabolism-like image, suggesting it as a valid surrogate marker for synaptic dysfunction, which could ultimately circumvent the need for additional FDG PET investigation in diagnosis of dementia. In recent years several [18F]-labelled amyloid PET tracers have been developed and have obtained clinical approval. There is accumulating evidence that early (post injection) acquisitions with these tracers are equally informative as conventional blood flow and metabolism studies for diagnosis of Alzheimer's disease, but there have been few side-by-side studies. Therefore, we investigated the performance of early acquisitions of [18F]-florbetaben (FBB) PET compared to [18F]-fluorodeoxyglucose (FDG) PET in a clinical setting. All subjects were recruited with clinical suspicion of dementia due to neurodegenerative disease. FDG PET was undertaken by conventional methods, and amyloid PET was performed with FBB, with early recordings for the initial 10min (early-phase FBB), and late recordings at 90–110min p.i. (late-phase FBB). Regional SUVR with cerebellar and global mean normalization were calculated for early-phase FBB and FDG PET. Pearson correlation coefficients between FDG and early-phase FBB were calculated for predefined cortical brain regions. Furthermore, a visual interpretation of disease pattern using 3-dimensional stereotactic surface projections (3D-SSP) was performed, with assessment of intra-reader agreement. Among a total of 33 patients (mean age 67.5±11.0years) included in the study, 18 were visually rated amyloid-positive, and 15 amyloid-negative based on late-phase FBB scans. Correlation coefficients for early-phase FBB vs. FDG scans displayed excellent agreement in all target brain regions for global mean normalization. Cerebellar normalization gave strong, but significantly lower correlations. 3D representations of early-phase FBB visually resembled the corresponding FDG PET images, irrespective of the amyloid-status of the late FBB scans. Early-phase FBB acquisitions correlate on a relative quantitative and visual level with FDG PET scans, irrespective of the amyloid plaque density assessed in late FBB imaging. Thus, early-phase FBB uptake depicts a metabolism-like image, suggesting it as a valid surrogate marker for synaptic dysfunction, which could ultimately circumvent the need for additional FDG PET investigation in diagnosis of dementia. •Early-phase [18F]-florbetaben uptake depicts a metabolism-like image•Strong relative quantitative and visual correlations of early-phase [18F]-florbetaben uptake with FDG images•A two-phase [18F]-florbetaben protocol might give combined neurodegeneration and amyloid pathology biomarker information•Early-phase [18F]-florbetaben PET could ultimately circumvent the need for an additional FDG-PET in the dementia work-up. • Early-phase [ 18 F]-florbetaben uptake depicts a metabolism-like image • Strong relative quantitative and visual correlations of early-phase [ 18 F]-florbetaben uptake with FDG images • A two-phase [ 18 F]-florbetaben protocol might give combined neurodegeneration and amyloid pathology biomarker information • Early-phase [ 18 F]-florbetaben PET could ultimately circumvent the need for an additional FDG-PET in the dementia work-up. AbstractObjectivesIn recent years several [ 18F]-labelled amyloid PET tracers have been developed and have obtained clinical approval. There is accumulating evidence that early (post injection) acquisitions with these tracers are equally informative as conventional blood flow and metabolism studies for diagnosis of Alzheimer's disease, but there have been few side-by-side studies. Therefore, we investigated the performance of early acquisitions of [ 18F]-florbetaben (FBB) PET compared to [ 18F]-fluorodeoxyglucose (FDG) PET in a clinical setting. MethodsAll subjects were recruited with clinical suspicion of dementia due to neurodegenerative disease. FDG PET was undertaken by conventional methods, and amyloid PET was performed with FBB, with early recordings for the initial 10 min (early-phase FBB), and late recordings at 90–110 min p.i. (late-phase FBB). Regional SUVR with cerebellar and global mean normalization were calculated for early-phase FBB and FDG PET. Pearson correlation coefficients between FDG and early-phase FBB were calculated for predefined cortical brain regions. Furthermore, a visual interpretation of disease pattern using 3-dimensional stereotactic surface projections (3D-SSP) was performed, with assessment of intra-reader agreement. ResultsAmong a total of 33 patients (mean age 67.5 ± 11.0 years) included in the study, 18 were visually rated amyloid-positive, and 15 amyloid-negative based on late-phase FBB scans. Correlation coefficients for early-phase FBB vs. FDG scans displayed excellent agreement in all target brain regions for global mean normalization. Cerebellar normalization gave strong, but significantly lower correlations. 3D representations of early-phase FBB visually resembled the corresponding FDG PET images, irrespective of the amyloid-status of the late FBB scans. ConclusionsEarly-phase FBB acquisitions correlate on a relative quantitative and visual level with FDG PET scans, irrespective of the amyloid plaque density assessed in late FBB imaging. Thus, early-phase FBB uptake depicts a metabolism-like image, suggesting it as a valid surrogate marker for synaptic dysfunction, which could ultimately circumvent the need for additional FDG PET investigation in diagnosis of dementia. In recent years several [ F]-labelled amyloid PET tracers have been developed and have obtained clinical approval. There is accumulating evidence that early (post injection) acquisitions with these tracers are equally informative as conventional blood flow and metabolism studies for diagnosis of Alzheimer's disease, but there have been few side-by-side studies. Therefore, we investigated the performance of early acquisitions of [ F]-florbetaben (FBB) PET compared to [ F]-fluorodeoxyglucose (FDG) PET in a clinical setting. All subjects were recruited with clinical suspicion of dementia due to neurodegenerative disease. FDG PET was undertaken by conventional methods, and amyloid PET was performed with FBB, with early recordings for the initial 10 min (early-phase FBB), and late recordings at 90-110 min p.i. (late-phase FBB). Regional SUVR with cerebellar and global mean normalization were calculated for early-phase FBB and FDG PET. Pearson correlation coefficients between FDG and early-phase FBB were calculated for predefined cortical brain regions. Furthermore, a visual interpretation of disease pattern using 3-dimensional stereotactic surface projections (3D-SSP) was performed, with assessment of intra-reader agreement. Among a total of 33 patients (mean age 67.5 ± 11.0 years) included in the study, 18 were visually rated amyloid-positive, and 15 amyloid-negative based on late-phase FBB scans. Correlation coefficients for early-phase FBB vs. FDG scans displayed excellent agreement in all target brain regions for global mean normalization. Cerebellar normalization gave strong, but significantly lower correlations. 3D representations of early-phase FBB visually resembled the corresponding FDG PET images, irrespective of the amyloid-status of the late FBB scans. Early-phase FBB acquisitions correlate on a relative quantitative and visual level with FDG PET scans, irrespective of the amyloid plaque density assessed in late FBB imaging. Thus, early-phase FBB uptake depicts a metabolism-like image, suggesting it as a valid surrogate marker for synaptic dysfunction, which could ultimately circumvent the need for additional FDG PET investigation in diagnosis of dementia. |
| Author | Danek, Adrian Patt, Marianne Schilling, Dorothee Bürger, Katharina Rominger, Axel Zacherl, Mathias Johannes Brendel, Matthias Daerr, Sonja Pogarell, Oliver Schildan, Andreas Zach, Christian Mille, Erik Barthel, Henryk Sabri, Osama Bartenstein, Peter |
| AuthorAffiliation | f SyNergy, Ludwig-Maximilians-Universität München, München, Germany d Dept. of Psychiatry, Ludwig-Maximilians-Universität München, München, Germany c Dept. of Neurology, Ludwig-Maximilians-Universität München, München, Germany g German Center for Neurodegenerative Diseases (DZNE), Munich, Germany b ISD, Ludwig-Maximilians-Universität München, München, Germany a Dept. of Nuclear Medicine, Ludwig-Maximilians-Universität München, München, Germany e Dept. of Nuclear Medicine, University of Leipzig, Leipzig, Germany |
| AuthorAffiliation_xml | – name: f SyNergy, Ludwig-Maximilians-Universität München, München, Germany – name: c Dept. of Neurology, Ludwig-Maximilians-Universität München, München, Germany – name: d Dept. of Psychiatry, Ludwig-Maximilians-Universität München, München, Germany – name: e Dept. of Nuclear Medicine, University of Leipzig, Leipzig, Germany – name: b ISD, Ludwig-Maximilians-Universität München, München, Germany – name: g German Center for Neurodegenerative Diseases (DZNE), Munich, Germany – name: a Dept. of Nuclear Medicine, Ludwig-Maximilians-Universität München, München, Germany |
| Author_xml | – sequence: 1 givenname: Sonja surname: Daerr fullname: Daerr, Sonja organization: Dept. of Nuclear Medicine, Ludwig-Maximilians-Universität München, München, Germany – sequence: 2 givenname: Matthias surname: Brendel fullname: Brendel, Matthias organization: Dept. of Nuclear Medicine, Ludwig-Maximilians-Universität München, München, Germany – sequence: 3 givenname: Christian surname: Zach fullname: Zach, Christian organization: Dept. of Nuclear Medicine, Ludwig-Maximilians-Universität München, München, Germany – sequence: 4 givenname: Erik surname: Mille fullname: Mille, Erik organization: Dept. of Nuclear Medicine, Ludwig-Maximilians-Universität München, München, Germany – sequence: 5 givenname: Dorothee surname: Schilling fullname: Schilling, Dorothee organization: Dept. of Nuclear Medicine, Ludwig-Maximilians-Universität München, München, Germany – sequence: 6 givenname: Mathias Johannes surname: Zacherl fullname: Zacherl, Mathias Johannes organization: Dept. of Nuclear Medicine, Ludwig-Maximilians-Universität München, München, Germany – sequence: 7 givenname: Katharina surname: Bürger fullname: Bürger, Katharina organization: ISD, Ludwig-Maximilians-Universität München, München, Germany – sequence: 8 givenname: Adrian surname: Danek fullname: Danek, Adrian organization: Dept. of Neurology, Ludwig-Maximilians-Universität München, München, Germany – sequence: 9 givenname: Oliver surname: Pogarell fullname: Pogarell, Oliver organization: Dept. of Psychiatry, Ludwig-Maximilians-Universität München, München, Germany – sequence: 10 givenname: Andreas surname: Schildan fullname: Schildan, Andreas organization: Dept. of Nuclear Medicine, University of Leipzig, Leipzig, Germany – sequence: 11 givenname: Marianne surname: Patt fullname: Patt, Marianne organization: Dept. of Nuclear Medicine, University of Leipzig, Leipzig, Germany – sequence: 12 givenname: Henryk surname: Barthel fullname: Barthel, Henryk organization: Dept. of Nuclear Medicine, University of Leipzig, Leipzig, Germany – sequence: 13 givenname: Osama surname: Sabri fullname: Sabri, Osama organization: Dept. of Nuclear Medicine, University of Leipzig, Leipzig, Germany – sequence: 14 givenname: Peter surname: Bartenstein fullname: Bartenstein, Peter organization: Dept. of Nuclear Medicine, Ludwig-Maximilians-Universität München, München, Germany – sequence: 15 givenname: Axel surname: Rominger fullname: Rominger, Axel email: axel.rominger@med.uni-muenchen.de organization: Dept. of Nuclear Medicine, Ludwig-Maximilians-Universität München, München, Germany |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28138429$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUl1rFDEUHaRia-0f8EHm0ZfZ5mMmk_FBkLLVQqGC7ZNISDI3bdZssk1mFvbfm9ndllaw5iWXm3NO7sd5Wxz44KEo3mM0wwiz08XMW-1mJMc5MUOoeVUcEYJphRtODp7Eh8VJSguUD0eoZexNcUg4prwm3VFxM19LN8rBBl8GU4KMblOt7mSC8ifm578q40JUMEgFvvw-vy6lvh9tsluC9aV2NtchXRnDOFgPpc7U9K54baRLcLK_j4ub8_n12bfq8urrxdmXy0qzlg4VUxRTpoFpybUG0_RE5xRopFSPe9YZjYAx2kiFW0ObDhENQGvVkLpDvKfHxcVOtw9yIVbRLmXciCCt2CZCvBUyDnlOIAxXjHIwXV-3NVYgmSKccWK0bhTjJmt93mmtRrWEXoMfonTPRJ-_eHsnbsNaNKRpEWmzwMe9QAz3I6RBLG3S4Jz0EMYkCKc1wV3H2X-hOGMylGCeoR-elvVYz8MKM4DsADqGlCKYRwhGYrKKWIjJKmKyypTLVskk_hdJ22HrgtyadS9T93OCvNi1hSgePPAbNpAWYYw-71xgkYhA4sfkw8mGmFE09ZUFPv1bIC_OvvT7H7RN7gw |
| CitedBy_id | crossref_primary_10_1007_s00259_020_04689_y crossref_primary_10_1007_s40336_020_00386_w crossref_primary_10_1002_acn3_70021 crossref_primary_10_3389_fnsys_2021_777706 crossref_primary_10_1016_j_ejrad_2021_109987 crossref_primary_10_1259_bjr_20211023 crossref_primary_10_2967_jnumed_117_200964 crossref_primary_10_1007_s13311_021_01027_4 crossref_primary_10_2967_jnumed_123_266273 crossref_primary_10_1111_cbdd_14162 crossref_primary_10_3390_diagnostics9020065 crossref_primary_10_1007_s00259_025_07175_5 crossref_primary_10_1007_s00259_024_07063_4 crossref_primary_10_1053_j_semnuclmed_2021_01_002 crossref_primary_10_1016_j_remn_2022_10_001 crossref_primary_10_1371_journal_pone_0211000 crossref_primary_10_1007_s40336_017_0257_4 crossref_primary_10_23736_S1824_4785_18_03069_8 crossref_primary_10_3389_fnagi_2021_661284 crossref_primary_10_3390_app122211463 crossref_primary_10_1097_RLU_0000000000005360 crossref_primary_10_1002_brx2_29 crossref_primary_10_1016_j_remn_2021_02_004 crossref_primary_10_1038_s41380_023_02215_8 crossref_primary_10_1177_0271678X19830537 crossref_primary_10_1002_trc2_12325 crossref_primary_10_1007_s00259_022_06087_y crossref_primary_10_2967_jnumed_122_264256 crossref_primary_10_1038_s41598_022_26811_w crossref_primary_10_3390_molecules25153413 crossref_primary_10_1097_RLU_0000000000002768 crossref_primary_10_1136_jmg_2023_109219 crossref_primary_10_1016_j_mednuc_2017_06_008 crossref_primary_10_1097_RLU_0000000000001952 crossref_primary_10_3390_brainsci12020146 crossref_primary_10_1007_s13139_022_00767_1 crossref_primary_10_1155_2018_6830105 crossref_primary_10_1016_j_cpet_2017_03_001 crossref_primary_10_1016_j_neucom_2020_06_081 crossref_primary_10_1016_j_nicl_2019_101978 crossref_primary_10_1016_j_nicl_2020_102535 crossref_primary_10_1038_s41598_021_95808_8 crossref_primary_10_1016_j_nicl_2023_103402 crossref_primary_10_1016_j_neuroimage_2021_117953 crossref_primary_10_1016_j_remnie_2023_02_001 crossref_primary_10_3390_medicina59071281 crossref_primary_10_1007_s13139_019_00612_y crossref_primary_10_1016_j_neuroimage_2018_03_045 crossref_primary_10_1111_ene_14743 crossref_primary_10_1186_s41824_021_00123_0 crossref_primary_10_1007_s00259_022_05846_1 crossref_primary_10_1038_s41598_021_91891_z crossref_primary_10_1016_j_jalz_2019_05_010 crossref_primary_10_1007_s00259_022_05964_w crossref_primary_10_3233_ADR_170023 crossref_primary_10_3233_JPD_212596 crossref_primary_10_3348_jksr_2022_0052 crossref_primary_10_1007_s00259_020_04788_w crossref_primary_10_3233_JAD_180274 crossref_primary_10_1088_1748_0221_15_10_P10026 crossref_primary_10_17340_jkna_2021_3_15 crossref_primary_10_3233_JAD_180232 crossref_primary_10_1002_alz_14414 crossref_primary_10_3390_app10072628 crossref_primary_10_1186_s13550_019_0499_4 crossref_primary_10_17340_jkna_2021_3_19 crossref_primary_10_1136_bmjopen_2019_032265 crossref_primary_10_30773_pi_2020_0214 crossref_primary_10_1016_j_neurobiolaging_2021_12_015 crossref_primary_10_3389_fnagi_2021_611595 crossref_primary_10_3988_jcn_2021_17_1_142 crossref_primary_10_1016_j_dadm_2018_08_012 crossref_primary_10_1007_s13139_020_00669_0 crossref_primary_10_1016_j_banm_2021_06_021 crossref_primary_10_1053_j_semnuclmed_2020_12_004 crossref_primary_10_3233_JAD_180050 crossref_primary_10_1017_cjn_2024_31 crossref_primary_10_1016_j_nicl_2019_101949 crossref_primary_10_1016_j_remnie_2021_03_016 crossref_primary_10_1007_s00259_024_06741_7 crossref_primary_10_3233_JAD_180522 crossref_primary_10_3390_s21155182 crossref_primary_10_1002_dad2_12601 crossref_primary_10_3389_fnagi_2018_00158 crossref_primary_10_1007_s00259_017_3832_z |
| Cites_doi | 10.3233/JAD-2011-0068 10.1007/s10967-010-0514-8 10.1016/j.jagp.2013.03.001 10.1002/hbm.10123 10.1007/s11604-007-0132-8 10.1016/j.jalz.2012.07.003 10.2967/jnumed.110.082057 10.1016/j.neurobiolaging.2010.03.011 10.2967/jnumed.112.116137 10.2174/1874440000802010114 10.1007/s00259-011-2051-2 10.1016/j.neuroimage.2009.01.057 10.1016/j.jalz.2008.05.2479 10.1093/cercor/bhn087 10.1016/S1474-4422(11)70077-1 10.1212/WNL.0b013e31826e9ae6 10.1007/s00259-016-3353-1 10.1371/journal.pone.0055415 10.1017/S1041610211000937 10.1007/s00259-013-2350-x 10.1016/j.neuint.2008.12.016 10.1016/j.neurobiolaging.2010.06.015 10.1016/j.jalz.2013.11.005 10.1006/nimg.1999.0431 10.1007/BF00308809 10.2967/jnumed.110.083683 |
| ContentType | Journal Article |
| Copyright | 2016 The Author(s) The Author(s) 2016 The Author(s) 2016 |
| Copyright_xml | – notice: 2016 The Author(s) – notice: The Author(s) – notice: 2016 The Author(s) 2016 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7S9 L.6 5PM DOA |
| DOI | 10.1016/j.nicl.2016.10.005 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic AGRICOLA AGRICOLA - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | AGRICOLA MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2213-1582 |
| EndPage | 86 |
| ExternalDocumentID | oai_doaj_org_article_f8b638ef9d4741bea6b28682fcc5b68f PMC5257027 28138429 10_1016_j_nicl_2016_10_005 1_s2_0_S2213158216301863 S2213158216301863 |
| Genre | Journal Article |
| GroupedDBID | .1- .FO 0R~ 1P~ 457 53G 5VS AAEDT AAEDW AAIKJ AALRI AAXUO AAYWO ABMAC ACGFS ACVFH ADBBV ADCNI ADEZE ADRAZ ADVLN AEUPX AEXQZ AFJKZ AFPUW AFRHN AFTJW AGHFR AIGII AITUG AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AOIJS APXCP BAWUL BCNDV DIK EBS EJD FDB GROUPED_DOAJ HYE HZ~ IPNFZ IXB KQ8 M41 M48 M~E O-L O9- OK1 RIG ROL RPM SSZ Z5R AFCTW AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7S9 L.6 5PM |
| ID | FETCH-LOGICAL-c673t-6b3136ce6ca8ccef5d2cb31ec0bbd1d69fc0e6635ab17f35902cee34b524908d3 |
| IEDL.DBID | M48 |
| ISSN | 2213-1582 |
| IngestDate | Wed Aug 27 01:25:35 EDT 2025 Thu Aug 21 13:12:40 EDT 2025 Fri Jul 11 00:27:10 EDT 2025 Fri Jul 11 15:24:29 EDT 2025 Mon Jul 21 06:07:41 EDT 2025 Tue Jul 01 01:09:16 EDT 2025 Thu Apr 24 23:01:00 EDT 2025 Wed Jun 18 06:48:26 EDT 2025 Tue Aug 26 17:37:56 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | C |
| Keywords | [18F]-florbetaben PET CBF FBB FDG GLM MNI CBL L SPECT 3D-SSP R Alzheimer's disease FDG Pet AD FTLD p.i CN Metabolism VOI PCC MCI Perfusion ß-amyloid SUVR PET [ 18F]-florbetaben PET volume of interest post injection cerebellum posterior cingulate cortex [ 18F]-fluorodeoxyglucose standardized uptake value ratio single photon emission computed tomography 3-dimensional stereotactic surface projections right Montreal Neurological Institute left [ 18 F]florbetaben cerebral blood flow mild cognitive impairment cognitively normal Positron emission tomography global mean frontotemporal lobar degeneration FDG, [18F]-fluorodeoxyglucose GLM, global mean MNI, Montreal Neurological Institute MCI, mild cognitive impairment FBB, [18F]florbetaben SUVR, standardized uptake value ratio p.i., post injection PCC, posterior cingulate cortex R, right VOI, volume of interest PET, Positron emission tomography L, left SPECT, single photon emission computed tomography CN, cognitively normal CBF, cerebral blood flow 3D-SSP, 3-dimensional stereotactic surface projections CBL, cerebellum FTLD, frontotemporal lobar degeneration AD, Alzheimer's disease |
| Language | English |
| License | This is an open access article under the CC BY license. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c673t-6b3136ce6ca8ccef5d2cb31ec0bbd1d69fc0e6635ab17f35902cee34b524908d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1016/j.nicl.2016.10.005 |
| PMID | 28138429 |
| PQID | 1863219218 |
| PQPubID | 23479 |
| PageCount | 10 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_f8b638ef9d4741bea6b28682fcc5b68f pubmedcentral_primary_oai_pubmedcentral_nih_gov_5257027 proquest_miscellaneous_2834219986 proquest_miscellaneous_1863219218 pubmed_primary_28138429 crossref_primary_10_1016_j_nicl_2016_10_005 crossref_citationtrail_10_1016_j_nicl_2016_10_005 elsevier_clinicalkeyesjournals_1_s2_0_S2213158216301863 elsevier_clinicalkey_doi_10_1016_j_nicl_2016_10_005 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2017-01-01 |
| PublicationDateYYYYMMDD | 2017-01-01 |
| PublicationDate_xml | – month: 01 year: 2017 text: 2017-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | NeuroImage clinical |
| PublicationTitleAlternate | Neuroimage Clin |
| PublicationYear | 2017 |
| Publisher | Elsevier Inc Elsevier |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier |
| References | Meyer, Hellwig, Amtage, Rottenburger, Sahm, Reuland, Weber, Hull (bb0095) 2011; 52 Blomquist, Engler, Nordberg, Ringheim, Wall, Forsberg, Estrada, Frandberg, Antoni, Langstrom (bb0015) 2008; 2 Joshi, Koeppe, Fessler (bb0070) 2009; 46 Herholz (bb0055) 2011; 23 Patt, Schildan, Barthel, Schultze-Mosgau, Rohde, Reininger, Sabri (bb0115) 2010; 284 Braak, Braak (bb0020) 1991; 82 Ziegler-Graham, Brookmeyer, Johnson, Arrighi (bb0150) 2008; 4 Tiepolt, Hesse, Patt, Luthardt, Schroeter, Hoffmann, Weise, Gertz, Sabri, Barthel (bb0145) 2016 Minoshima, Frey, Koeppe, Foster, Kuhl (bb0100) 1995; 36 Barthel, Sabri (bb0005) 2011; 26 Kadir, Almkvist, Forsberg, Wall, Engler, Langstrom, Nordberg (bb0075) 2012; 33 Rostomian, Madison, Rabinovici, Jagust (bb0120) 2011; 52 Hsiao, Huang, Hsieh, Wey, Kung, Yen, Lin (bb0065) 2013; 40 Hsiao, Huang, Hsieh, Hsu, Wey, Yen, Kung, Lin (bb0060) 2012; 39 Shokouhi, Claassen, Kang, Ding, Rogers, Mishra, Riddle (bb0125) 2013; 54 Lim, Ellis, Pietrzak, Ames, Darby, Harrington, Martins, Masters, Rowe, Savage, Szoeke, Villemagne, Maruff, A. R. Group (bb0080) 2012; 79 Meyer, Gunn, Myers, Grasby (bb0090) 1999; 9 Gur, Ragland, Reivich, Greenberg, Alavi, Gur (bb0045) 2009; 19 Furst, Rabinovici, Rostomian, Steed, Alkalay, Racine, Miller, Jagust (bb0040) 2012; 33 Hammers, Allom, Koepp, Free, Myers, Lemieux, Mitchell, Brooks, Duncan (bb0050) 2003; 19 Dishino, Welch, Kilbourn, Raichle (bb0025) 1983; 24 Barthel, Gertz, Dresel, Peters, Bartenstein, Buerger, Hiemeyer, Wittemer-Rump, Seibyl, Reininger, Sabri (bb0010) 2011; 10 Nihashi, Yatsuya, Hayasaka, Kato, Kawatsu, Arahata, Iwai, Takeda, Washimi, Yoshimura, Mizuno, Kato, Naganawa, Ito (bb0105) 2007; 25 Dukart, Perneczky, Forster, Barthel, Diehl-Schmid, Draganski, Obrig, Santarnecchi, Drzezga, Fellgiebel, Frackowiak, Kurz, Muller, Sabri, Schroeter, Yakushev (bb0035) 2013; 8 Donaghy, Thomas, O'Brien (bb0030) 2015; 23 Lim, Maruff, Pietrzak, Ellis, Darby, Ames, Harrington, Martins, Masters, Szoeke, Savage, Villemagne, Rowe, A. R. Group (bb0085) 2014; 10 Svedberg, Hall, Hellstrom-Lindahl, Estrada, Guan, Nordberg, Langstrom (bb0140) 2009; 54 Ossenkoppele, Prins, Pijnenburg, Lemstra, van der Flier, Adriaanse, Windhorst, Handels, Wolfs, Aalten, Verhey, Verbeek, van Buchem, Hoekstra, Lammertsma, Scheltens, van Berckel (bb0110) 2013; 9 Silverman (bb0130) 2004; 45 Spehl, Hellwig, Frings, Bormann, Meyer (bb0135) 2015; 54 Silverman (10.1016/j.nicl.2016.10.005_bb0130) 2004; 45 Lim (10.1016/j.nicl.2016.10.005_bb0080) 2012; 79 Nihashi (10.1016/j.nicl.2016.10.005_bb0105) 2007; 25 Patt (10.1016/j.nicl.2016.10.005_bb0115) 2010; 284 Minoshima (10.1016/j.nicl.2016.10.005_bb0100) 1995; 36 Hsiao (10.1016/j.nicl.2016.10.005_bb0065) 2013; 40 Blomquist (10.1016/j.nicl.2016.10.005_bb0015) 2008; 2 Dishino (10.1016/j.nicl.2016.10.005_bb0025) 1983; 24 Hammers (10.1016/j.nicl.2016.10.005_bb0050) 2003; 19 Joshi (10.1016/j.nicl.2016.10.005_bb0070) 2009; 46 Barthel (10.1016/j.nicl.2016.10.005_bb0005) 2011; 26 Braak (10.1016/j.nicl.2016.10.005_bb0020) 1991; 82 Gur (10.1016/j.nicl.2016.10.005_bb0045) 2009; 19 Meyer (10.1016/j.nicl.2016.10.005_bb0090) 1999; 9 Donaghy (10.1016/j.nicl.2016.10.005_bb0030) 2015; 23 Tiepolt (10.1016/j.nicl.2016.10.005_bb0145) 2016 Herholz (10.1016/j.nicl.2016.10.005_bb0055) 2011; 23 Ossenkoppele (10.1016/j.nicl.2016.10.005_bb0110) 2013; 9 Svedberg (10.1016/j.nicl.2016.10.005_bb0140) 2009; 54 Spehl (10.1016/j.nicl.2016.10.005_bb0135) 2015; 54 Dukart (10.1016/j.nicl.2016.10.005_bb0035) 2013; 8 Shokouhi (10.1016/j.nicl.2016.10.005_bb0125) 2013; 54 Barthel (10.1016/j.nicl.2016.10.005_bb0010) 2011; 10 Hsiao (10.1016/j.nicl.2016.10.005_bb0060) 2012; 39 Lim (10.1016/j.nicl.2016.10.005_bb0085) 2014; 10 Furst (10.1016/j.nicl.2016.10.005_bb0040) 2012; 33 Rostomian (10.1016/j.nicl.2016.10.005_bb0120) 2011; 52 Ziegler-Graham (10.1016/j.nicl.2016.10.005_bb0150) 2008; 4 Kadir (10.1016/j.nicl.2016.10.005_bb0075) 2012; 33 Meyer (10.1016/j.nicl.2016.10.005_bb0095) 2011; 52 |
| References_xml | – volume: 45 start-page: 594 year: 2004 end-page: 607 ident: bb0130 article-title: Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging publication-title: J. Nucl. Med. – volume: 24 start-page: 1030 year: 1983 end-page: 1038 ident: bb0025 article-title: Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals publication-title: J. Nucl. Med. – volume: 33 start-page: 215 year: 2012 end-page: 225 ident: bb0040 article-title: Cognition, glucose metabolism and amyloid burden in Alzheimer's disease publication-title: Neurobiol. Aging – volume: 284 start-page: 557 year: 2010 end-page: 562 ident: bb0115 article-title: Metabolite analysis of [18 publication-title: J. Radioanal. Nucl. Chem. – volume: 54 start-page: 1564 year: 2013 end-page: 1569 ident: bb0125 article-title: Longitudinal progression of cognitive decline correlates with changes in the spatial pattern of brain 18F-FDG PET publication-title: J. Nucl. Med. – volume: 23 start-page: 23 year: 2015 end-page: 37 ident: bb0030 article-title: Amyloid PET imaging in Lewy body disorders publication-title: Am. J. Geriatr. Psychiatry – volume: 8 year: 2013 ident: bb0035 article-title: Reference cluster normalization improves detection of frontotemporal lobar degeneration by means of FDG-PET publication-title: PLoS One – volume: 82 start-page: 239 year: 1991 end-page: 259 ident: bb0020 article-title: Neuropathological stageing of Alzheimer-related changes publication-title: Acta Neuropathol. – volume: 52 start-page: 393 year: 2011 end-page: 400 ident: bb0095 article-title: Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B publication-title: J. Nucl. Med. – volume: 54 start-page: A7V7 year: 2015 ident: bb0135 article-title: Einfluss der zerebralen Beta-Amyloid Pathologie auf R1-basierte Bildgebung zerebraler Perfusion mittels C-11-PIB-PET: Hinweise auf eine Störung der Fluss/Metabolismus-Kopplung? publication-title: Nucl. Med. – volume: 40 start-page: 908 year: 2013 end-page: 920 ident: bb0065 article-title: Perfusion-like template and standardized normalization-based brain image analysis using 18F-florbetapir (AV-45/Amyvid) PET publication-title: Eur. J. Nucl. Med. Mol. Imaging – volume: 10 start-page: 424 year: 2011 end-page: 435 ident: bb0010 article-title: Cerebral amyloid-beta PET with florbetaben ((18)F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study publication-title: Lancet Neurol. – volume: 10 start-page: 743 year: 2014 end-page: 751 ident: bb0085 article-title: Abeta and cognitive change: Examining the preclinical and prodromal stages of Alzheimer's disease publication-title: Alzheimers Dement. – volume: 9 start-page: 414 year: 2013 end-page: 421 ident: bb0110 article-title: Impact of molecular imaging on the diagnostic process in a memory clinic publication-title: Alzheimers Dement. – volume: 46 start-page: 154 year: 2009 end-page: 159 ident: bb0070 article-title: Reducing between scanner differences in multi-center PET studies publication-title: NeuroImage – volume: 2 start-page: 114 year: 2008 end-page: 125 ident: bb0015 article-title: Unidirectional influx and net accumulation of PIB publication-title: Open Neuroimaging J. – volume: 36 start-page: 1238 year: 1995 end-page: 1248 ident: bb0100 article-title: A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET publication-title: J. Nucl. Med. – volume: 9 start-page: 545 year: 1999 end-page: 553 ident: bb0090 article-title: Assessment of spatial normalization of PET ligand images using ligand-specific templates publication-title: NeuroImage – volume: 79 start-page: 1645 year: 2012 end-page: 1652 ident: bb0080 article-title: Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults publication-title: Neurology – volume: 19 start-page: 224 year: 2003 end-page: 247 ident: bb0050 article-title: Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe publication-title: Hum. Brain Mapp. – volume: 4 start-page: 316 year: 2008 end-page: 323 ident: bb0150 article-title: Worldwide variation in the doubling time of Alzheimer's disease incidence rates publication-title: Alzheimers Dement. – year: 2016 ident: bb0145 article-title: Early [18 publication-title: Eur. J. Nucl. Med. Mol. Imaging – volume: 23 start-page: S25 year: 2011 end-page: S31 ident: bb0055 article-title: Perfusion SPECT and FDG-PET publication-title: Int. Psychogeriatr. – volume: 39 start-page: 613 year: 2012 end-page: 620 ident: bb0060 article-title: Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies publication-title: Eur. J. Nucl. Med. Mol. Imaging – volume: 25 start-page: 255 year: 2007 end-page: 262 ident: bb0105 article-title: Direct comparison study between FDG-PET and IMP-SPECT for diagnosing Alzheimer's disease using 3D-SSP analysis in the same patients publication-title: Radiat. Med. – volume: 54 start-page: 347 year: 2009 end-page: 357 ident: bb0140 article-title: [(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients publication-title: Neurochem. Int. – volume: 26 start-page: 117 year: 2011 end-page: 121 ident: bb0005 article-title: Florbetaben to trace amyloid-beta in the Alzheimer brain by means of PET publication-title: J. Alzheimers Dis. – volume: 19 start-page: 375 year: 2009 end-page: 382 ident: bb0045 article-title: Regional differences in the coupling between resting cerebral blood flow and metabolism may indicate action preparedness as a default state publication-title: Cereb. Cortex – volume: 33 year: 2012 ident: bb0075 article-title: Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease publication-title: Neurobiol. Aging – volume: 52 start-page: 173 year: 2011 end-page: 179 ident: bb0120 article-title: Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients publication-title: J. Nucl. Med. – volume: 26 start-page: 117 issue: Suppl 3 year: 2011 ident: 10.1016/j.nicl.2016.10.005_bb0005 article-title: Florbetaben to trace amyloid-beta in the Alzheimer brain by means of PET publication-title: J. Alzheimers Dis. doi: 10.3233/JAD-2011-0068 – volume: 284 start-page: 557 year: 2010 ident: 10.1016/j.nicl.2016.10.005_bb0115 article-title: Metabolite analysis of [18F]Florbetaben (BAY 94-9172) in human subjects: a substudy within a proof of mechanism clinical trial publication-title: J. Radioanal. Nucl. Chem. doi: 10.1007/s10967-010-0514-8 – volume: 23 start-page: 23 issue: 1 year: 2015 ident: 10.1016/j.nicl.2016.10.005_bb0030 article-title: Amyloid PET imaging in Lewy body disorders publication-title: Am. J. Geriatr. Psychiatry doi: 10.1016/j.jagp.2013.03.001 – volume: 19 start-page: 224 issue: 4 year: 2003 ident: 10.1016/j.nicl.2016.10.005_bb0050 article-title: Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe publication-title: Hum. Brain Mapp. doi: 10.1002/hbm.10123 – volume: 25 start-page: 255 issue: 6 year: 2007 ident: 10.1016/j.nicl.2016.10.005_bb0105 article-title: Direct comparison study between FDG-PET and IMP-SPECT for diagnosing Alzheimer's disease using 3D-SSP analysis in the same patients publication-title: Radiat. Med. doi: 10.1007/s11604-007-0132-8 – volume: 9 start-page: 414 issue: 4 year: 2013 ident: 10.1016/j.nicl.2016.10.005_bb0110 article-title: Impact of molecular imaging on the diagnostic process in a memory clinic publication-title: Alzheimers Dement. doi: 10.1016/j.jalz.2012.07.003 – volume: 52 start-page: 173 issue: 2 year: 2011 ident: 10.1016/j.nicl.2016.10.005_bb0120 article-title: Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients publication-title: J. Nucl. Med. doi: 10.2967/jnumed.110.082057 – volume: 24 start-page: 1030 issue: 11 year: 1983 ident: 10.1016/j.nicl.2016.10.005_bb0025 article-title: Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals publication-title: J. Nucl. Med. – volume: 33 start-page: 215 issue: 2 year: 2012 ident: 10.1016/j.nicl.2016.10.005_bb0040 article-title: Cognition, glucose metabolism and amyloid burden in Alzheimer's disease publication-title: Neurobiol. Aging doi: 10.1016/j.neurobiolaging.2010.03.011 – volume: 54 start-page: 1564 issue: 9 year: 2013 ident: 10.1016/j.nicl.2016.10.005_bb0125 article-title: Longitudinal progression of cognitive decline correlates with changes in the spatial pattern of brain 18F-FDG PET publication-title: J. Nucl. Med. doi: 10.2967/jnumed.112.116137 – volume: 2 start-page: 114 year: 2008 ident: 10.1016/j.nicl.2016.10.005_bb0015 article-title: Unidirectional influx and net accumulation of PIB publication-title: Open Neuroimaging J. doi: 10.2174/1874440000802010114 – volume: 39 start-page: 613 issue: 4 year: 2012 ident: 10.1016/j.nicl.2016.10.005_bb0060 article-title: Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies publication-title: Eur. J. Nucl. Med. Mol. Imaging doi: 10.1007/s00259-011-2051-2 – volume: 46 start-page: 154 issue: 1 year: 2009 ident: 10.1016/j.nicl.2016.10.005_bb0070 article-title: Reducing between scanner differences in multi-center PET studies publication-title: NeuroImage doi: 10.1016/j.neuroimage.2009.01.057 – volume: 54 start-page: A7V7 issue: 2 year: 2015 ident: 10.1016/j.nicl.2016.10.005_bb0135 article-title: Einfluss der zerebralen Beta-Amyloid Pathologie auf R1-basierte Bildgebung zerebraler Perfusion mittels C-11-PIB-PET: Hinweise auf eine Störung der Fluss/Metabolismus-Kopplung? publication-title: Nucl. Med. – volume: 36 start-page: 1238 issue: 7 year: 1995 ident: 10.1016/j.nicl.2016.10.005_bb0100 article-title: A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET publication-title: J. Nucl. Med. – volume: 45 start-page: 594 issue: 4 year: 2004 ident: 10.1016/j.nicl.2016.10.005_bb0130 article-title: Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging publication-title: J. Nucl. Med. – volume: 4 start-page: 316 issue: 5 year: 2008 ident: 10.1016/j.nicl.2016.10.005_bb0150 article-title: Worldwide variation in the doubling time of Alzheimer's disease incidence rates publication-title: Alzheimers Dement. doi: 10.1016/j.jalz.2008.05.2479 – volume: 19 start-page: 375 issue: 2 year: 2009 ident: 10.1016/j.nicl.2016.10.005_bb0045 article-title: Regional differences in the coupling between resting cerebral blood flow and metabolism may indicate action preparedness as a default state publication-title: Cereb. Cortex doi: 10.1093/cercor/bhn087 – volume: 10 start-page: 424 issue: 5 year: 2011 ident: 10.1016/j.nicl.2016.10.005_bb0010 article-title: Cerebral amyloid-beta PET with florbetaben ((18)F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(11)70077-1 – volume: 79 start-page: 1645 issue: 16 year: 2012 ident: 10.1016/j.nicl.2016.10.005_bb0080 article-title: Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults publication-title: Neurology doi: 10.1212/WNL.0b013e31826e9ae6 – year: 2016 ident: 10.1016/j.nicl.2016.10.005_bb0145 article-title: Early [18F]florbetaben and [11C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer's disease publication-title: Eur. J. Nucl. Med. Mol. Imaging doi: 10.1007/s00259-016-3353-1 – volume: 8 issue: 2 year: 2013 ident: 10.1016/j.nicl.2016.10.005_bb0035 article-title: Reference cluster normalization improves detection of frontotemporal lobar degeneration by means of FDG-PET publication-title: PLoS One doi: 10.1371/journal.pone.0055415 – volume: 23 start-page: S25 issue: Suppl 2 year: 2011 ident: 10.1016/j.nicl.2016.10.005_bb0055 article-title: Perfusion SPECT and FDG-PET publication-title: Int. Psychogeriatr. doi: 10.1017/S1041610211000937 – volume: 40 start-page: 908 issue: 6 year: 2013 ident: 10.1016/j.nicl.2016.10.005_bb0065 article-title: Perfusion-like template and standardized normalization-based brain image analysis using 18F-florbetapir (AV-45/Amyvid) PET publication-title: Eur. J. Nucl. Med. Mol. Imaging doi: 10.1007/s00259-013-2350-x – volume: 54 start-page: 347 issue: 5–6 year: 2009 ident: 10.1016/j.nicl.2016.10.005_bb0140 article-title: [(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients publication-title: Neurochem. Int. doi: 10.1016/j.neuint.2008.12.016 – volume: 33 issue: 1 year: 2012 ident: 10.1016/j.nicl.2016.10.005_bb0075 article-title: Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease publication-title: Neurobiol. Aging doi: 10.1016/j.neurobiolaging.2010.06.015 – volume: 10 start-page: 743 issue: 6 year: 2014 ident: 10.1016/j.nicl.2016.10.005_bb0085 article-title: Abeta and cognitive change: Examining the preclinical and prodromal stages of Alzheimer's disease publication-title: Alzheimers Dement. doi: 10.1016/j.jalz.2013.11.005 – volume: 9 start-page: 545 issue: 5 year: 1999 ident: 10.1016/j.nicl.2016.10.005_bb0090 article-title: Assessment of spatial normalization of PET ligand images using ligand-specific templates publication-title: NeuroImage doi: 10.1006/nimg.1999.0431 – volume: 82 start-page: 239 issue: 4 year: 1991 ident: 10.1016/j.nicl.2016.10.005_bb0020 article-title: Neuropathological stageing of Alzheimer-related changes publication-title: Acta Neuropathol. doi: 10.1007/BF00308809 – volume: 52 start-page: 393 issue: 3 year: 2011 ident: 10.1016/j.nicl.2016.10.005_bb0095 article-title: Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B publication-title: J. Nucl. Med. doi: 10.2967/jnumed.110.083683 |
| SSID | ssj0000800766 |
| Score | 2.4129357 |
| Snippet | In recent years several [18F]-labelled amyloid PET tracers have been developed and have obtained clinical approval. There is accumulating evidence that early... AbstractObjectivesIn recent years several [ 18F]-labelled amyloid PET tracers have been developed and have obtained clinical approval. There is accumulating... In recent years several [ F]-labelled amyloid PET tracers have been developed and have obtained clinical approval. There is accumulating evidence that early... OBJECTIVESIn recent years several [18F]-labelled amyloid PET tracers have been developed and have obtained clinical approval. There is accumulating evidence... • Early-phase [ 18 F]-florbetaben uptake depicts a metabolism-like image • Strong relative quantitative and visual correlations of early-phase [ 18... Objectives: In recent years several [18F]-labelled amyloid PET tracers have been developed and have obtained clinical approval. There is accumulating evidence... |
| SourceID | doaj pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 77 |
| SubjectTerms | [18F]-florbetaben PET Aged Alzheimer's disease Amyloidogenic Proteins - metabolism Aniline Compounds - metabolism Dementia - diagnostic imaging Dementia - etiology FDG Pet Female Humans Imaging, Three-Dimensional - methods Male Metabolism Middle Aged Neurodegenerative Diseases - complications Perfusion Positron-Emission Tomography Radiology Regular Statistics as Topic Stereotaxic Techniques Stilbenes - metabolism Time Factors ß-amyloid |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bi9QwFA6yD-KLeLfeiOCbRJukSTOPKjMsgiK4AwsiITlN2FmWzroz8_89p5dh6mV98amQJmlz8qXnS3PyhbFXUNnSQZKiKW0QlQxGRAO1MDLQzsuGFMMp2uKzPV5WH0_N6cFRXxQT1ssD94Z7m11EiKQ8ayp0fjEFG5WzTmUAE63L9PVFn3cwmTofeFDdLVQqJbWQxqlhx0wf3EWqsxTXZd90oV1m4pU68f6Jc_qdfP4aQ3nglBZ32O2BTfJ3fSvushupvcdufhrWy--z5Xwv5s3XmSdSMxaXZ-i5-DfpFt9Fxul6TNsQU8u_zE94gB-7VR_GxVctH_dN8qs1ArRNHLDo5gFbLuYnH47FcJCCAFvrrbBRS20hWQgOIGXTKMCkBGWMjWzsLEOZiHqEKOusSdEFfaeuolG0Ltjoh-yoXbfpMeMGK5GuzqDBoP_TM5NkbPCqwIQUc8HkaEgPg8o4HXZx4cdwsnNPxvdkfEpD4xfs9b7MZa-xcW3u99Q_-5ykj90lIGr8gBr_L9QUTI-960dT4kcTK1pd--j6T6XSZhj3Gy_9RvnSfyXUEeiQ7ZbSWV2wlyOEPI5fWpQJbVrvsATeVSRK5_6eBylgpWgzpC3Yox52--YrJ7VDUoHvNgHkxD7TO-3qrNMR704wVPWT_2HQp-yWIsLT_Zx6xo62V7v0HOnaNr7oRuZP8c885w priority: 102 providerName: Directory of Open Access Journals |
| Title | Evaluation of early-phase [18F]-florbetaben PET acquisition in clinical routine cases |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2213158216301863 https://www.clinicalkey.es/playcontent/1-s2.0-S2213158216301863 https://www.ncbi.nlm.nih.gov/pubmed/28138429 https://www.proquest.com/docview/1863219218 https://www.proquest.com/docview/2834219986 https://pubmed.ncbi.nlm.nih.gov/PMC5257027 https://doaj.org/article/f8b638ef9d4741bea6b28682fcc5b68f |
| Volume | 14 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3daxQxEA-1gvgifnt-lAi-yZZNssnmHkRU7ihCRbAHBZGQzCb2Stlt7wPa_96Zvd2rp2cffFrIZvYjM8n8djPzG8beQGFyC1FkVW58Vgivs6ChzLTwlHlZEWM4RVt8MQeT4vOxPt5hfbmjbgDnWz_tqJ7UZHa2f3lx9R4n_LvrWC0ikaUwLbPfRmrpW-w2eqaSKhocdnD_tENHpTFd7sx2UWIHtkLZogWd166qZfTf8Fh_I9I_Ayt_81Tj--xeBzH5h5VNPGA7sX7I7hx2m-iP2GS0ZvjmTeKRKI6z8xN0Z_y7sOMfWcJv-BAXPsSafx0dcQ8Xy-kqtotPa94nU_JZg1ZbRw4oOn_MJuPR0aeDrKuukIEp1SIzQQllIBrwFiAmXUnApgh5CJWozDBBHgmP-CDKpIjmBR2qKoKWtFlYqSdst27q-IxxjRcRtkygQKNTVEMdRajwKEH7GNKAiX4gHXTU41QB48z1MWanjvTgSA_UhnoYsLdrmfMV8caNvT-SftY9iTS7bWhmP103B12yAVebmIZVgTgqRG-CtMbKBKCDsfiYqteu64cSV1K80PTGW5fbpOK8t2Un3Fy63H2TUihBickGV1Vr1IC97k3I4aSmnRpfx2aJEnhWElOd_XcfxIWFpAxJM2BPV2a3fv3egvHZNgxyY3w2z9TTk5ZcvC1rKMvn_y35gt2VBH3a31Qv2e5itoyvELgtwl77w2OvnZO_AN9aQ7Y |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+early-phase+%5B18F%5D-florbetaben+PET+acquisition+in+clinical+routine+cases&rft.jtitle=NeuroImage+clinical&rft.au=Daerr%2C+Sonja&rft.au=Brendel%2C+Matthias&rft.au=Zach%2C+Christian&rft.au=Mille%2C+Erik&rft.date=2017-01-01&rft.pub=Elsevier&rft.eissn=2213-1582&rft.volume=14&rft.spage=77&rft.epage=86&rft_id=info:doi/10.1016%2Fj.nicl.2016.10.005&rft_id=info%3Apmid%2F28138429&rft.externalDocID=PMC5257027 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F22131582%2FS2213158217X00028%2Fcov150h.gif |